Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Langer, Rupert"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 56
Tytuł:
Risk factors for esophageal cancer: emphasis on infectious agents.
Autorzy:
El-Zimaity H; Dynacare Laboratories, Brampton, Ontario, Canada.
Di Pilato V; Department of Clinical and Experimental Medicine, University of Florence, Florence, Italy.
Novella Ringressi M; Department of Surgery and Translational Medicine, University of Florence, Florence, Italy.; Gastrointestinal Surgery Unit, Florence Careggi University Hospital, Florence, Italy.
Brcic I; Institute of Pathology, Medical University of Graz, Graz, Austria.
Rajendra S; Gastro-Intestinal Viral Oncology Group, Ingham Institute for Applied Medical Research, Liverpool, Sydney, New South Wales, Australia.; South Western Sydney Clinical School, University of New South Wales, Kensington, Sydney, New South Wales, Australia.; Department of Gastroenterology & Hepatology, Bankstown-Lidcombe Hospital, South Western Sydney Local Health Network, Bankstown, Sydney, New South Wales, Australia.
Langer R; Institute of Pathology, University of Bern, Bern, Switzerland.
Dislich B; Institute of Pathology, Kantonsspital Baselland, Liestal, Switzerland.
Tripathi M; Cambridge University Hospitals, NHS Foundation Trust, Cambridge, UK.
Guindi M; Department of Pathology and laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California.
Riddell R; Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada.
Pokaż więcej
Źródło:
Annals of the New York Academy of Sciences [Ann N Y Acad Sci] 2018 Dec; Vol. 1434 (1), pp. 319-332. Date of Electronic Publication: 2018 May 31.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Adenocarcinoma*/metabolism
Adenocarcinoma*/microbiology
Adenocarcinoma*/pathology
Adenocarcinoma*/virology
Barrett Esophagus*/metabolism
Barrett Esophagus*/microbiology
Barrett Esophagus*/pathology
Barrett Esophagus*/virology
Epstein-Barr Virus Infections*/metabolism
Epstein-Barr Virus Infections*/microbiology
Epstein-Barr Virus Infections*/pathology
Epstein-Barr Virus Infections*/virology
Esophageal Neoplasms*/metabolism
Esophageal Neoplasms*/microbiology
Esophageal Neoplasms*/pathology
Esophageal Neoplasms*/virology
Esophagus*/microbiology
Esophagus*/pathology
Esophagus*/virology
Gastroesophageal Reflux*/metabolism
Gastroesophageal Reflux*/microbiology
Gastroesophageal Reflux*/pathology
Gastroesophageal Reflux*/virology
Helicobacter Infections*/metabolism
Helicobacter Infections*/microbiology
Helicobacter Infections*/pathology
Helicobacter Infections*/virology
Helicobacter pylori/metabolism ; Herpesvirus 4, Human/metabolism ; Humans ; Keratoderma, Palmoplantar, Diffuse/metabolism ; Keratoderma, Palmoplantar, Diffuse/microbiology ; Keratoderma, Palmoplantar, Diffuse/pathology ; Keratoderma, Palmoplantar, Diffuse/virology ; Risk Factors
SCR Disease Name:
Adenocarcinoma Of Esophagus
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Her2-Targeted Therapy Induces Autophagy in Esophageal Adenocarcinoma Cells.
Autorzy:
Janser FA; Institute of Pathology, University of Bern, Murtenstrasse 31, 3008 Bern, Switzerland. .; Graduate School for Cellular and Biomedical Sciences, University of Bern, Freiestr. 1, 3012 Bern, Switzerland. .
Adams O; Institute of Pathology, University of Bern, Murtenstrasse 31, 3008 Bern, Switzerland. .; Graduate School for Cellular and Biomedical Sciences, University of Bern, Freiestr. 1, 3012 Bern, Switzerland. .
Bütler V; Institute of Pathology, University of Bern, Murtenstrasse 31, 3008 Bern, Switzerland. .
Schläfli AM; Institute of Pathology, University of Bern, Murtenstrasse 31, 3008 Bern, Switzerland. .
Dislich B; Institute of Pathology, University of Bern, Murtenstrasse 31, 3008 Bern, Switzerland. .
Seiler CA; Department of Visceral Surgery and Medicine, University Hospital Bern, 3010 Bern, Switzerland. .
Kröll D; Department of Visceral Surgery and Medicine, University Hospital Bern, 3010 Bern, Switzerland. .
Langer R; Institute of Pathology, University of Bern, Murtenstrasse 31, 3008 Bern, Switzerland. rupert.langer@pathology.unibe.ch.
Tschan MP; Institute of Pathology, University of Bern, Murtenstrasse 31, 3008 Bern, Switzerland. .; Graduate School for Cellular and Biomedical Sciences, University of Bern, Freiestr. 1, 3012 Bern, Switzerland. .
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2018 Oct 08; Vol. 19 (10). Date of Electronic Publication: 2018 Oct 08.
Typ publikacji:
Journal Article
MeSH Terms:
Adenocarcinoma/*drug therapy
Antineoplastic Agents/*pharmacology
Autophagy/*drug effects
Esophageal Neoplasms/*drug therapy
Lapatinib/*pharmacology
Adenocarcinoma/metabolism ; Antineoplastic Agents/therapeutic use ; Cell Line, Tumor ; Drug Resistance, Neoplasm ; Esophageal Neoplasms/metabolism ; HEK293 Cells ; Humans ; Lapatinib/therapeutic use ; Receptor, ErbB-2/antagonists & inhibitors
SCR Disease Name:
Adenocarcinoma Of Esophagus
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
A specific expression profile of LC3B and p62 is associated with nonresponse to neoadjuvant chemotherapy in esophageal adenocarcinomas.
Autorzy:
Adams O; Institute of Pathology, University of Bern, Bern, Switzerland.; Graduate School for Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland.
Janser FA; Institute of Pathology, University of Bern, Bern, Switzerland.; Graduate School for Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland.
Dislich B; Institute of Pathology, University of Bern, Bern, Switzerland.
Berezowska S; Institute of Pathology, University of Bern, Bern, Switzerland.
Humbert M; Institute of Pathology, University of Bern, Bern, Switzerland.
Seiler CA; Department of Visceral Surgery and Medicine, Inselspital University Hospital Bern and University of Bern, Bern, Switzerland.
Kroell D; Department of Visceral Surgery and Medicine, Inselspital University Hospital Bern and University of Bern, Bern, Switzerland.
Slotta-Huspenina J; Institute of Pathology, Technische Universität München, München, Germany.
Feith M; Department of Surgery, Klinikum Rechts der Isar, Technische Universität München, München, Germany.
Ott K; Department of Surgery, RoMED Klinikum, Rosenheim, Germany.
Tschan MP; Institute of Pathology, University of Bern, Bern, Switzerland.; Graduate School for Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland.
Langer R; Institute of Pathology, University of Bern, Bern, Switzerland.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2018 Jun 13; Vol. 13 (6), pp. e0197610. Date of Electronic Publication: 2018 Jun 13 (Print Publication: 2018).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Adenocarcinoma/*drug therapy
Esophageal Neoplasms/*drug therapy
Microtubule-Associated Proteins/*genetics
RNA-Binding Proteins/*genetics
Adenocarcinoma/genetics ; Adenocarcinoma/pathology ; Adult ; Aged ; Autophagy/genetics ; Biopsy ; Disease-Free Survival ; Esophageal Neoplasms/genetics ; Esophageal Neoplasms/pathology ; Female ; Gene Expression Regulation, Neoplastic ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Neoadjuvant Therapy/adverse effects ; Paclitaxel/administration & dosage ; Paclitaxel/adverse effects ; Transcription Factors
SCR Disease Name:
Adenocarcinoma Of Esophagus
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Tumour border configuration in colorectal cancer: proposal for an alternative scoring system based on the percentage of infiltrating margin.
Autorzy:
Karamitopoulou E; Institute of Pathology, Clinical Pathology Division, University of Bern, Bern, Switzerland.; Translational Research Unit, University of Bern, Bern, Switzerland.
Zlobec I; Translational Research Unit, University of Bern, Bern, Switzerland.
Koelzer VH; Institute of Pathology, Clinical Pathology Division, University of Bern, Bern, Switzerland.; Translational Research Unit, University of Bern, Bern, Switzerland.
Langer R; Institute of Pathology, Clinical Pathology Division, University of Bern, Bern, Switzerland.; Translational Research Unit, University of Bern, Bern, Switzerland.
Dawson H; Institute of Pathology, Clinical Pathology Division, University of Bern, Bern, Switzerland.; Translational Research Unit, University of Bern, Bern, Switzerland.
Lugli A; Institute of Pathology, Clinical Pathology Division, University of Bern, Bern, Switzerland.; Translational Research Unit, University of Bern, Bern, Switzerland.
Pokaż więcej
Źródło:
Histopathology [Histopathology] 2015 Oct; Vol. 67 (4), pp. 464-73. Date of Electronic Publication: 2015 Mar 23.
Typ publikacji:
Journal Article
MeSH Terms:
Adenocarcinoma/*pathology
Colorectal Neoplasms/*pathology
Neoplasm Staging/*methods
Adenocarcinoma/mortality ; Adult ; Aged ; Colorectal Neoplasms/mortality ; Female ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Prognosis ; Proportional Hazards Models
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Image analysis of immunohistochemistry is superior to visual scoring as shown for patient outcome of esophageal adenocarcinoma.
Autorzy:
Feuchtinger A; Research Unit Analytical Pathology, German Research Center for Environmental Health, Institute of Pathology, Helmholtz Zentrum München, Ingolstädter Landstraße 1, 85764, Neuherberg, Germany, .
Stiehler T
Jütting U
Marjanovic G
Luber B
Langer R
Walch A
Pokaż więcej
Źródło:
Histochemistry and cell biology [Histochem Cell Biol] 2015 Jan; Vol. 143 (1), pp. 1-9. Date of Electronic Publication: 2014 Aug 26.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Image Processing, Computer-Assisted*
Adenocarcinoma/*diagnosis
Esophageal Neoplasms/*diagnosis
Adenocarcinoma/surgery ; Esophageal Neoplasms/surgery ; Female ; Humans ; Immunohistochemistry ; Male ; Middle Aged ; Observation ; Prognosis ; Survival Analysis
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Adenocarcinoma at the gastroesophageal junction.
Autorzy:
Al-Haddad S; Department of Laboratory Medicine and Pathobiology, St. Michael's Hospital, Toronto, Canada.
Chang AC
De Hertogh G
Grin A
Langer R
Sagaert X
Salemme M
Streutker CJ
Soucy G
Tripathi M
Upton MP
Vieth M
Villanacci V
Pokaż więcej
Źródło:
Annals of the New York Academy of Sciences [Ann N Y Acad Sci] 2014 Sep; Vol. 1325, pp. 211-25.
Typ publikacji:
Congress
MeSH Terms:
Adenocarcinoma/*diagnosis
Esophageal Neoplasms/*diagnosis
Esophagogastric Junction/*pathology
Stomach Neoplasms/*diagnosis
Adenocarcinoma/therapy ; Animals ; Esophageal Neoplasms/therapy ; Esophagoscopy/methods ; Humans ; Paris ; Stomach Neoplasms/therapy
SCR Disease Name:
Adenocarcinoma Of Esophagus
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
A retrospective comparative exploratory study on two methylentetrahydrofolate reductase (MTHFR) polymorphisms in esophagogastric cancer: the A1298C MTHFR polymorphism is an independent prognostic factor only in neoadjuvantly treated gastric cancer patients.
Autorzy:
Blank S
Rachakonda S
Keller G
Weichert W
Lordick F
Langer R
Springfeld C
Bruckner T
Becker K
Kumar R
Ott K; Department of Surgery, University Hospital of Heidelberg, Im Neuenheimer Feld 110, Heidelberg 69120, Germany. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2014 Feb 03; Vol. 14, pp. 58. Date of Electronic Publication: 2014 Feb 03.
Typ publikacji:
Comparative Study; Journal Article; Multicenter Study
MeSH Terms:
Esophagogastric Junction*/pathology
Esophagogastric Junction*/surgery
Neoadjuvant Therapy*
Polymorphism, Genetic*
Adenocarcinoma/*genetics
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Esophageal Neoplasms/*genetics
Methylenetetrahydrofolate Reductase (NADPH2)/*genetics
Stomach Neoplasms/*genetics
Adenocarcinoma/enzymology ; Adenocarcinoma/mortality ; Adenocarcinoma/pathology ; Adenocarcinoma/therapy ; Chemotherapy, Adjuvant ; Esophageal Neoplasms/enzymology ; Esophageal Neoplasms/mortality ; Esophageal Neoplasms/pathology ; Esophageal Neoplasms/therapy ; Esophagectomy ; Female ; Gastrectomy ; Gene Frequency ; Genetic Predisposition to Disease ; Germany ; Humans ; Kaplan-Meier Estimate ; Male ; Multivariate Analysis ; Phenotype ; Proportional Hazards Models ; Retrospective Studies ; Risk Factors ; Stomach Neoplasms/enzymology ; Stomach Neoplasms/mortality ; Stomach Neoplasms/pathology ; Stomach Neoplasms/therapy ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Discovery of new molecular subtypes in oesophageal adenocarcinoma.
Autorzy:
Berg D; Institute of Pathology, Technische Universität München, Munich, Germany.
Wolff C
Langer R
Schuster T
Feith M
Slotta-Huspenina J
Malinowsky K
Becker KF
Pokaż więcej
Źródło:
PloS one [PLoS One] 2011; Vol. 6 (9), pp. e23985. Date of Electronic Publication: 2011 Sep 23.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Adenocarcinoma/*metabolism
Biomarkers, Tumor/*analysis
Esophageal Neoplasms/*metabolism
Proteomics/*methods
Adenocarcinoma/pathology ; Adult ; Aged ; Aged, 80 and over ; Cluster Analysis ; Esophageal Neoplasms/pathology ; Female ; HSP27 Heat-Shock Proteins/analysis ; Humans ; Kaplan-Meier Estimate ; Lymphatic Metastasis ; Male ; Middle Aged ; Prognosis ; Proportional Hazards Models ; Proteome/analysis ; Proteome/classification ; Proteomics/statistics & numerical data ; Receptor, ErbB-2/analysis ; Tissue Array Analysis
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
High number of CD45RO+ tumor infiltrating lymphocytes is an independent prognostic factor in non-metastasized (stage I-IIA) esophageal adenocarcinoma.
Autorzy:
Rauser S; Institute of Pathology, Helmholtz Zentrum München, German Research Center for Environmental Health, Ingolstaedter Landstr. 1, 85764 Neuherberg, Germany.
Langer R
Tschernitz S
Gais P
Jütting U
Feith M
Höfler H
Walch A
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2010 Nov 05; Vol. 10, pp. 608. Date of Electronic Publication: 2010 Nov 05.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Gene Expression Regulation, Neoplastic*
Adenocarcinoma/*metabolism
Adenocarcinoma/*pathology
Esophageal Neoplasms/*metabolism
Esophageal Neoplasms/*pathology
Leukocyte Common Antigens/*biosynthesis
Lymphocytes, Tumor-Infiltrating/*metabolism
Adenocarcinoma/diagnosis ; Adult ; Aged ; Aged, 80 and over ; CD3 Complex/biosynthesis ; CD8 Antigens/biosynthesis ; Esophageal Neoplasms/diagnosis ; Female ; Humans ; Immune System ; Male ; Middle Aged ; Multivariate Analysis ; Prognosis ; Recurrence ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Coping with esophageal cancer approaches worldwide.
Autorzy:
Cotton, Richard G.H. (AUTHOR)
Langer, Rupert (AUTHOR)
Leong, Trevor (AUTHOR)
Martinek, Jan (AUTHOR)
Sewram, Vikash (AUTHOR)
Smithers, Mark (AUTHOR)
Swanson, Paul E. (AUTHOR)
Qiao, You‐Lin (AUTHOR)
Udagawa, Harushi (AUTHOR)
Ueno, Masaki (AUTHOR)
Wang, Meng (AUTHOR)
Wei, Wen‐Qiang (AUTHOR)
White, Russell E. (AUTHOR)
Pokaż więcej
Źródło:
Annals of the New York Academy of Sciences. 2014, Vol. 1325 Issue 1, p138-158. 21p. 3 Diagrams, 5 Charts, 3 Graphs.
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Expression and clinical significance of Glucose Regulated Proteins GRP78 (BiP) and GRP94 (GP96) in human adenocarcinomas of the esophagus.
Autorzy:
Langer, Rupert Rupert.Langer@lrz.tu-muenchen.de
Feith, Marcus
Siewert, Joerg Rüdiger
Wester, Hans-Juergen
Hoefler, Heinz
Pokaż więcej
Źródło:
BMC Cancer. 2008, Vol. 8, Special section p1-9. 9p. 1 Color Photograph, 6 Charts, 1 Graph.
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Wyświetlanie 1-20 z 56

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies